OPK

OPK

USD

OPKO Health Inc. Common Stock

$1.410+0.040 (2.920%)

Preço em tempo real

Healthcare
Diagnostics & Research
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$1.370

Máximo

$1.430

Mínimo

$1.370

Volume

2.69M

Fundamentos da empresa

Capitalização de mercado

1.1B

Setor

Diagnostics & Research

País

United States

Estatísticas de negociação

Volume médio

2.21M

Bolsa de valores

NMS

Moeda

USD

Faixa de 52 semanas

Mínimo $1.11Atual $1.410Máximo $2.04

Notícias relacionadas

Analyst Upgrades

Jefferies Downgrades OPKO Health to Hold, Lowers Price Target to $1.6

Jefferies analyst Maury Raycroft downgrades OPKO Health from Buy to Hold and lowers the price target from $2 to $1.6.

Ver mais
Jefferies Downgrades OPKO Health to Hold, Lowers Price Target to $1.6
Analyst Upgrades

Barrington Research Maintains Outperform on OPKO Health, Maintains $2.25 Price Target

Barrington Research analyst Michael Petusky maintains OPKO Health with a Outperform and maintains $2.25 price target.

Ver mais
Barrington Research Maintains Outperform on OPKO Health, Maintains $2.25 Price Target
GlobeNewswire

OPKO Health's ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications

Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) --

Ver mais
OPKO Health's ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
GlobeNewswire

OPKO Health's ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers

First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 WESTON, Mass., Oct. 28,

Ver mais
OPKO Health's ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers
GlobeNewswire

OPKO Health to Report Third Quarter 2025 Financial Results on October 29

MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial

Ver mais
OPKO Health to Report Third Quarter 2025 Financial Results on October 29

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.